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Estradiol (E2) and progesterone (P4) collaborate within bone remodelling on resorption (E2) and formation (P4). We integrate
evidencethatP4 maypreventand,withantiresorptives,treatwomen’sosteoporosis.P4 stimulatesosteoblastdiﬀerentiationinvitro.
Menarche(E2)and onset of ovulation (P4)both contributeto peak BMD. Meta-analysis of 5 studiesconﬁrms thatregularly cycling
premenopausal women lose bone mineral density (BMD) related to subclinical ovulatory disturbances (SODs). Cyclic progestin
prevents bone loss in healthy premenopausal women with amenorrhea or SOD. BMD loss is more rapid in perimenopause than
postmenopause—decreased bone formation due to P4 deﬁciency contributes. In 4 placebo-controlled RCTs, BMD loss is not
prevented by P4 in postmenopausal women with increased bone turnover. However, 5 studies of E2-MPA co-therapy show greater
BMD increases versus E2 alone. P4 fracture data are lacking. P4 prevents bone loss in pre- and possibly perimenopausal women;
progesterone co-therapy with antiresorptives may increase bone formation and BMD.
1.Introduction
Osteoporosis has been considered primarily because of
estrogen deﬁciency at menopause since Fuller Albright [1].
Most scientists view estradiol as women’s sole bone-active
gonadal steroid. In reality, estradiol and progesterone work
together in every tissue in women’s normal physiology [2].
Estrogen plays positive roles in bone biology and osteoporo-
sis prevention and treatment primarily through decreasing
bone resorption [3–5]. There is also compelling evidence
that powerful bone-destructive cytokines such as IL-1, IL-6,
and TNFα are released and increase rapidly with dropping
estradiol levels, as occurs with surgical menopause [6].
Estradiol achieves its positive bone eﬀects largely through
two key actions: facilitation of vitamin D-related intestinal
calcium absorption [4, 7] and suppression of bone resorp-
tion through the osteoprotegerin/RANK/RANKL system [7].
It is also clinically obvious that premenopausal women
with amenorrhea have lower estradiol levels and lower bone
mineral density (BMD) and/or lose bone rapidly [8].
Not until recently did randomized, placebo-controlled
trial data from the WHI studies show that treatment with
conjugated equine estrogen (CEE) plus medroxyproges-
terone (MPA) or with CEE alone (in women with hysterec-
tomy) prevented osteoporotic fractures in asymptomatic
postmenopausal women ages 50–79 [5, 9]. Estradiol’s role in
human bone health is unmistakable. However, progesterone
is usually a present, but an unrecognized partner in bone.
With amenorrhea and surgical or natural menopause, not
only are estradiol levels low or dropping, progesterone levels
are also low. While, in these conditions, estrogen and proges-
terone deﬁciency are nearly indistinguishable, progesterone
deﬁciency precedes low estradiol levels in perimenopause
[10], for example, and with ovulatory disturbances, occurs
silently in regular cycles with normal estrogen levels
[11].
The purpose of this paper and meta-analyses is to
study recent clinical evidence that endogenous proges-
terone plays a role in bone health. So far, three in vitro
publications document progesterone’s ability to increase2 Journal of Osteoporosis
osteoblast numbers [12–14]a sw e l la si t se ﬀects to promote
osteoblast maturation and diﬀerentiation [13]. Progesterone
appears to play a diﬀering but also physiological role in
partnership with estrogen in achieving optimal peak bone
mass. Medroxyprogesterone increases premenopausal spine
BMD as physiological-dose cyclic therapy in a randomized
controlled trial (RCT) for healthy women experiencing
hypothalamic amenorrhea, oligomenorrhea, anovulation, or
short luteal phase cycles [15].
Progesterone may also have a therapeutic role in post-
menopausal osteoporosis if paired with an antiresorptive
therapy. Thus this paper highlights the accumulating human
evidence for a role of progesterone for increasing bone
formationinestrogen-repletewomenwithregularmenstrual
cycles.
From a teleological point of view, a higher trabecular
bone mass in women is needed in preparation for building
of the fetal skeleton during pregnancy. Interestingly, the
third trimester of pregnancy, during which 80% of the fetal
skeleton is mineralized, coincides with the maximum rate
of progesterone production in human physiology. Under
normal circumstances, enough trabecular bone has been
accumulated and maintained in women’s skeletons to serve
as a reservoir for the calcium needs of both mother and fetus
during the months of pregnancy, and for the infant during
potential months of breast-feeding. The fact that bone
morphogenic proteins play a crucial role in both ovulation
and bone metabolism points towards a functional link
between bone and reproductive systems aimed at preparing
for the increased demands of pregnancy.
Knowledge of progesterone’s actions in the context of
the latest genetic, receptor, and bone ligand systems is in
its infancy—relationships may well exist between proges-
terone and the immune system through osteoblast and
hematopoietic stem cell interactions in bone marrow [16],
through progesterone’s known brain anti-inﬂammatory and
antiapoptotic actions [17], and through potential rela-
tionships with emerging bone-related molecules such as
sclerostin, vascular endothelial growth factor (VEGF), and
basic ﬁbroblast growth factor (bFGF), to name a few. These
molecular biology issues, however, are beyond the scope of
this primarily clinical and therapeutic review.
Over the last 20 years [14], a number of controlled trials
and prospective studies suggest that progesterone may have
a role in treatment of pre- or perimenopausal women with
regular, estrogen-suﬃcient menstrual cycles who, however,
are also experiencing ovulatory disturbances (anovulation,
or short luteal phase length cycles). The most prevalent
of abnormal cycles are subclinical ovulatory disturbances
(SOD) that are unremarkable because they occur within reg-
ular, asymptomatic menstrual cycles [11, 18]. They have an
increased incidence in normal weight women with subclin-
ical cognitive dietary restraint [19], women working shifts
and in stressful environments. However, currently there are
no published data about eﬀects of progesterone on human
bone architecture and bone quantitative histomorphometry
in either the cortical or cancellous bone compartments, or
about the potential of molecularly identical progesterone to
decrease fracture risk.
2.MaterialsandMethods
Studies on endogenous and/or physiologic progesterone
concentrations and bone are very scarce: a PubMed search
carried out in January, 2010 using the MeSH terms “endoge-
nous progesterone and bone” yielded 51 results since 1975.
Similarly, 83 papers since 1968 were found using the terms
“physiological progesterone and bone.” We excluded all
citations concerning animals and/or nonhuman cell lines
(most of which have been previously reviewed [14]), those
relating to preterm infants, and publications on synthetic
androgenic or estrogenic progestins, depot-MPA or other
injectable progestins, or those in supraphysiological doses.
This paper will focus on the physiological and pharma-
ceutical actions of progesterone and/or “physiological dose”
medroxyprogesterone acetate (MPA) as the progesterone-
derived therapy most commonly prescribed in the USA and
Canada. It is important to note that, when using the word,
“progesterone,” we are always discussing the native human
steroid.
If reference to the actions of a progestin or progestogen
is required, this paper will speciﬁcally state the compound
involved. NETA—and other progestins that primarily are
metabolized to estrogen or that act through androgen
osteoblast receptors—is not covered because our focus
is on physiological bone actions of the human steroid,
progesterone.
Given our broad purpose, we are evaluating data from
diverse sources; we are also, of necessity, comparing stud-
ies with diﬀering methodologies and designs. Therefore,
although numerical summaries are created where possible,
we have not subjected these combined data to statistical
analysis.
3. Results and Discussion
3.1. Progesterone and Bone Formation in Osteoblasts. Most
studies of the action of progesterone on human osteoblasts
in vitro have assessed eﬀects over a maximum of only 72
hours’ duration [12–14]. One recent study from Munich,
however, used long-term cultures of human osteoblasts
(HOBs) to characterize the inﬂuence of progesterone and
estradiol on bone proliferation (using a hexosaminidase
assay) and diﬀerentiation (using alkaline phosphatase [ALP]
staining).ThisstudyquantiﬁedALPproductionphotometri-
cally with extinction at 405nm following incubation with p-
Nitrophenyl-Phosphate (pNPP) and buﬀer [20]( Figure 1).
These primary osteoblast cultures, derived from nonosteo-
poroticperimenopausalwomenundergoinghipreplacement
s u r g e r y ,w e r ee x p o s e dt o7o r2 1d a y so fp r o g e s t e r o n ew i t h
and without estradiol pre- and cotreatment [20].
The eﬀect of progesterone in vitro ond i ﬀerentiation of
osteoblasts was dose-dependent for progesterone [20], inde-
pendent of estradiol, and reached its maximal stimulation
at concentrations of 10−9 Mp r o g e s t e r o n e( Figure 1). This
progesterone level corresponds with luteal phase serum pro-
gesterone levels in ovulatory cycles. Seven days of exposure
to physiologic levels of progesterone (6.4 × 10−7–10−9 M)
led to increased ALP concentrationsof 70% (P = .004–.019),Journal of Osteoporosis 3
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Figure 1: This photomicrograph (at 400 power magniﬁcation) shows human osteoblasts in culture after 28 days stained to show Alkaline
Phosphatase production as dark blue. (a) Estradiol at a physiological concentration. (b) Estradiol alone for 7 days combined with
Progesterone for 21 days. Note the lack of alkaline phosphatase staining in (a) exposed to estrogen alone, and the marked ALP staining
indicating osteoblast diﬀerentiation/maturation induced by the addition of progesterone, (b) This ﬁgure is reprinted from [20] with
permission from authors (Schmidmayr M and Seifert-Klauss V). Publisher permission provided.
while a supraphysiological progesterone concentration (6.4
× 10−6 M) caused a signiﬁcant 50% reduction in ALP
(P = .028). After 21 days of physiological progesterone
exposure, the ALP production increased 2.7-fold (P = .000
to .004). At supraphysiological progesterone concentrations
ALP staining decreased by 80% (P = .03). Thus there
was a physiological osteoblast diﬀerentiation dose-response
curve optimal at luteal phase levels with suppression at
high progesterone doses. In contrast to expectation and the
observations of others [13], this eﬀect was independent of
pre- or cotreatment with estradiol. Proliferation, however,
was not signiﬁcantly aﬀected by progesterone in the absence
ofestradiol[20].Theseresultssuggestanosteoanabolicfunc-
tion of progesterone, while showing for the ﬁrst time that
supraphysiological progesterone concentrations suppressed
osteoblast diﬀerentiation. These data are the longest of any
in vitro data on human osteoblasts and progesterone. They
clearly show a progesterone osteoblast diﬀerentiation dose
response and independence from estradiol.
3.2. Progesterone and Bone within Menstrual Cycles,
Relation to Peak Bone Mass, and Premenopausal
Bone Loss Prevention
3.2.1. Progesterone and Bone Remodeling in the Menstrual
Cycle. During the bone remodeling cycle within a single
bone multicellular unit (BMU), activation is followed by
increased resorption, which in turn is followed by osteoid
formation and osteoid mineralization [21]. Within a single
BMU, formation takes approximately two to three weeks
while formation and initial (incomplete) mineralization
requiresatleastthreemonths[21].Perhapsincompensation,
osteoblastsappeartobemoreabundantandalsomoreplastic
than osteoclasts and evolve to become both lining cells and
osteocytes [22].
Although a number of studies have been performed
of bone turnover markers across the menstrual cycle [14],
most of them used less precise or speciﬁc markers and
methods, inadequately diﬀerentiated ovulatory from anovu-
latory cycles (by hormonal measures), or recorded too few
cycles to be helpful. Some studies with careful cycle bone
marker documentation are now available [23, 24] and tend
to show increased follicular phase urinary markers of bone
resorption in addition to increased luteal phase markers
of bone formation. Chiu et al. found the bone resorption
marker deoxypyridinoline (D-Pyr) to be higher during the
follicular phase than in the luteal phase and to correlate
negatively both with E2 v a l u e sm e a s u r e d6a n d8d a y s
earlier and with progesterone levels measured 2–6 days
earlier [23]. Unfortunately, the authors did not diﬀerentiate
between ovulatory and anovulatory cycles, which judging
from the wide span of progesterone values must have been
mixed in their study. They concluded that “normal women
experience monthly episodes of increased bone resorption
from menarche to menopause” [23]. In another study, 10
Japanese women with normal ovulatory function showed
signiﬁcant decreases in CTX, free D-Pyr, and serum intact
carboxyterminal telopeptide (ICTP) during the luteal phase
and signiﬁcantly higher serum PTH levels during the follicu-
lar than the luteal phase [25], perhaps because of coupling
of resorption and formation. Caufriez et al. very recently
proposed a potential role of endogenous progesterone in
modulationofGH-secretion(alongwithprolactinandTRH)
during the normal menstrual cycle [26]. In their study of 10
young Belgian women, 24-hour growth hormone secretion
was associated with higher progesterone levels, and daytime
GH secretion was increased in the luteal phase compared
with the follicular phase [26]. Another European group had
already found that PTH concentrations were highest on
day three of the menstrual cycle, but had not monitored
ovulation and found no relation to progesterone levels [27].4 Journal of Osteoporosis
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Figure 2: This diagram illustrates changes in Total Body (black
circle) and Spine (black square) Bone Mineral Content (BMC)
adjusted for body size in a population-based cohort of adolescents
(mean 11.8 years old) by Tanner Stages on the X-axis. It is drawn
from data in Table 3 [28]. Endocrine Society permission provided.
Earlier,aDanishserialserumhormonestudyineighthealthy
women aged 20–47 found osteoblastic activity to be higher
during the well-documented luteal phase by measurements
of osteocalcin (OC) and bone-speciﬁc alkaline phosphatase
(BAP) [24]. In addition, this study also observed the highest
level of IGF-1 (then called somatomedin C) during the
luteal phase of the menstrual cycle [24], with which the
recent growth hormone data agree [26]. Thus several studies
conﬁrm higher follicular phase bone resorption rates and
higher luteal phase rates of bone formation.
3.2.2. Progesterone, Ovulation, and Peak Bone Mass. Young
women gain body size (BMI), bone size, and BMD rapidly
around the time of peak height velocity and menarche [29,
30]. Although not well characterized, it is known that levels
of estradiol, testosterone, and growth hormone are increased
during this period of bone growth and reproductive matu-
ration. However, ovulatory cycles are rare at menarche and
become more prevalent only with increasing time since the
ﬁrstperiod[31,32].Therearesparsedataaboutrelationships
between bone change and ovulation, documented either by
Tanner breast stages (in which Tanner stages 4 and 5 indicate
the presence of progesterone [33]) and/or by hormonal
measures.
A recent population-based study of estradiol receptor
polymorphisms and BMC data (corrected for bone area but
not BMI or body size) compared BMC with breast Tanner
Stage in a cross-sectional study of girls who averaged aged
11.8. These data showed that bone size-adjusted BMC is
greater in Tanner Stage 5 than in Stage 1 (Figure 2)[ 28].
Such cross-sectional population-based data ﬁt with
p r o s p e c t i v eo b s e r v a t i o n si nt h eT e e nB o n eS t u d y[ 30], a
prospective, observational study in a convenience cohort
of 38 girls aged 9–11 (mean initial age 10.6 ± [SD]
0.6 years) that documented total body and spine BMD
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Figure 3: This graph shows the multivariable regression for the
mean and the 95% conﬁdence interval of the change in total body
bone mineral density (BMD) over 3 years in relationship to time
since menarche in 38 peripubertal girls studied prospectively [30].
The vertical line shows the earliest, in a subset of 13 girls who
provided menstrual calendar data and salivary progesterone levels,
that ovulation could be diagnosed [34]. Reprinted with permission
of the authors. Society for Bone and Mineral Research permission
provided.
and BMC at baseline and yearly. In addition six monthly
measurements were made of weight, height, seated height,
wrist width, BMI, and questionnaires about calcium intakes
and exercise [30]. These young women were also examined
every six months for pubertal maturation. The onset of
menstruation, menstrual cycle calendar data, and weekly
salivaryprogesteronelevelswereusedtoassesstheprevalence
of ovulation based on a threshold value of higher than
40nmol/L [34, 35].
Menarche occurred for 33 young women during the
course of the 3-year study [34]. Based on 93 menstrual cycles
from 13 young women that averaged 36 days long (range 20–
119) and their weekly salivary progesterone data (n = 163
samples), 27 (29%) cycles were ovulatory while 66 (71%)
wereanovulatory.Ovulationwasdocumentednoearlierthan
10 ± 5 months postmenarche [34]. Figure 3 shows that
total body BMD increased signiﬁcantly by the number of
days since menarche (day 0 in Figure 3); in particular BMD
increased more following the onset of ovulation [34]. Gains
in bone density were greater 10 ± 5 months after menarche
following which time ovulation ﬁrst developed (shown with
the dotted vertical line) than before (r2 = 0.40, P<. 0001).
It is known that pubertal bone gain strongly relates to body
size and weight. Despite the observation that BMI increased
with time following menarche, no signiﬁcant relationship
between changes in BMI and changes in spine BMD or BMC
was found. However, changes in BMI did signiﬁcantly relate
to changes in total body BMC (r = .421, P = .001). In
summary, these prospective teen bone and ovulation data,
although limited, suggest that progesterone adds to the bone
gains of menarche. Following the onset of ovulation (that is
delayed on average for almost a year after menarche) bone
gain is greater than early after menarche suggesting thatJournal of Osteoporosis 5
progesterone contributes to a high ideal peak bone mass in
adolescent girls [36].
3.2.3. Menstrual Cycle Disturbances and Bone (Amenorrhea
and Oligomenorrhea). Absence of menstruation following
menarche is associated with low levels of both estradiol and
progesterone, whether related to hypothalamic suppression
(usually due to calorie insuﬃciency for the level of energy
expenditure, emotional/social stressors, or physical illness)
or to ovarian dysfunction (such as Turner’s Syndrome or
other causes of premature menopause). In general, longer
cycle lengths are associated with lower estradiol levels and
BMD values [37, 38]. In some young women, however,
oligomenorrhea is related to anovulatory androgen excess
(AAE, as in “polycystic ovary syndrome,” PCOS) and associ-
atedwithhigherLH,testosterone,DHEAS,androstenedione,
and estrogen levels, but absent or rare ovulation and abso-
lute or relative progesterone deﬁciency [39]. Because these
oligomenorrheic, hyperandrogenic young women likely have
diﬀerent changes in bone compared to regularly cyclic or to
amenorrheic women, and their prospective bone changes are
notwellcharacterized,wewillnotreviewAAE/PCOSfurther
here.
Epidemiologicaldatasuggestthatprimaryamenorrheais
rare in the population (about 0.1%) [40]; secondary amen-
orrhea is also uncommon (<1.3%) in the premenopausal
population, although it is more prevalent in teen-aged
population-based samples [41, 42]. Both hypothalamic
amenorrhea and oligomenorrhea are associated with sig-
niﬁcantly lower BMD values as well as lower FSH levels
[43]. Furthermore, there is rapid bone loss after the onset
of amenorrhea [44]. However, with longer durations of
amenorrhea (more than three years), bone turnover and
bone loss both appear to decrease [36] while absolute BMD
values remain low. Thus, among premenopausal women,
long cycles associated with hypothalamic oligomenorrhea
and amenorrhea are both risk factors for bone loss and low
BMD.
3.2.4. Ovulatory Disturbances (Anovulation/Short Luteal
Phases) and Bone in Regular Cycles. Regular cycles with
normal estradiol levels may vary in their progesterone
characteristics. Such cycles may be normally ovulatory,
anovulatory or have short luteal phase lengths that result
in decreased total progesterone production [11]. Subclinical
ovulatory disturbances (SODs, meaning regular cycles with
either anovulation and short luteal phase lengths) may pose
a risk for bone remodelling imbalance and bone loss despite
regular, estrogen-suﬃcient menstrual cycles.
Currently ﬁve published observational cohort studies in
a total of 458 women have prospectively examined menstrual
cycles by ovulatory characteristics and change in BMD
[11, 45–48]m e a s u r e db yd u a le n e r g yX - r a ya b s o r p t i o m e t r y
measures (DXA) or spinal quantitative computed tomo-
graphy (QCT). These studies span one to four years in
healthy, largely Caucasian premenopausal women (ages 20–
42) not using oral contraceptives (OCs) or other bone-active
therapies.DocumentationoflutealphaselengthsusedQuan-
titative BasalTemperature(QBT)methods (validatedagainst
the serum LH peak [49] and daily urinary progesterone
excretion by pregnanediol (PdG), resp. [50]).
Ovulatory characteristics are variously described in the
ﬁve studies. Table 1 shows the similarities and diﬀerences
among these published studies—all are in primarily well-
educated, white women who average >10 years since menar-
cheandaremainlyintheir30s(meanage31.4)exceptforthe
younger women (mean age 22.1) in the Bedford study [48].
In these ﬁve studies assessing prospective bone change
by the incidence of ovulatory disturbances, the total number
of cycles with documentation of ovulation (Table 1)v a r i e d
from a median of 10/year in the Prior 1990 study to 5/year in
the Waugh investigation, to 6.8/year in the Bedford study, to
2.7/year in the Waller, and 1.5/year in the Prior 1996 data.
In this latter four-year follow-up study, women collected
menstrual cycle and QBT data for 3–6 months at the end of
the fourth year and before repeat BMD measurement at the
ﬁve-year anniversary of their initial QCT. Here, the median
number of cycles of data collected by the 27 reported women
was 6 (range 3–46) with a minimum of 3 cycles [45].
In those three studies that had documentation of ovula-
tioninatleastﬁvecycles/year,whichreachedatotalofalmost
400 women, those with more prevalent normally ovulatory
cycles had a +1.23% gain versus the −1.00% loss/year in
those with ovulatory disturbances (Table 1)[ 11, 46, 48].
By contrast, studies with fewer cycles between bone density
measurements [45] or few measurements not within the
bone change window [47] were not able to show any such
ovulation-bone change relationship [45, 47]. However, the
luteal index (mean luteal phase length divided by mean cycle
length) from year one of the Prior study [11]c o n t i n u e dt o
relate positively (r = 0.339. P = .043) to the entire ﬁve-
year bone change [45]. Also in the total body bone density
reported by Waller, normally cycling women experienced
a +0.02% change while those with ovulatory disturbances
experienced a –1.7% loss (P = .08) [47]. Furthermore,
the Bedford study showed that total hip BMD change, in
additiontospinalBMD,wassigniﬁcantlyrelatedtoovulatory
disturbances (−0.6% versus +0.9%, P = .001) [48]. In
summary, it appears that ﬁve or more cycles of ovulation-
documented data per year are needed to “see” any bone
change related to progesterone production within regular
menstrual cycles.
Several cross-sectional studies have also addressed the
issue of ovulation and BMD. The most inﬂuential of these
has a nested case-control design within a population-based
sample (The Michigan Bone Health Study) [54]. A randomly
sampled cohort of premenopausal women ages 25–45 (n =
582) all had BMD measured by DXA. Those in the lowest
10th percentile of bone density (cases) and those in the
50th to 75th percentile of BMD (controls), who had regular
cycles, were on no hormones (n = 31 cases and 34
controls) collected daily ﬁrst morning urines for LH, FSH,
and excretory products of estrogen (E1C) and progesterone
(PdG) over two cycles or 84 days [54]. Cases (women with
low BMD) were smaller and leaner than controls (BMI 23.6
versus 26.1), probably of lower socioeconomic status (based
on signiﬁcantly fewer years of education) and were less likely
to use alcohol or to have taken oral contraceptives [28].6 Journal of Osteoporosis
Table 1: Prospective studies of spinal Bone Mineral Density (BMD) change by ovulatory menstrual cycles compared with ovulatory
disturbances (anovulation and short luteal phases within normal length cycles). BMD is by Quantitative Computed Tomography (∗)o r
Dual Energy X-ray Absorptiometry (+). All data are shown as mean ± SD.
Manuscript Number
women
Duration
(years)
Age ± SD
(range)
Body Mass
Index # Cycles/year Cycle length
(days)
% Bone change/year-spine
Normal
• Ovulatory
disturbances
Prior 1990 [15] 66 1 33.7 ±7.1
(20–42)
22.0
(18–24.9)
10 (6 to 13
cycles) 28.2 ±2.6( ∗)+ 0 . 2 ( ∗)– 3 . 3
Prior 1996 [51] 27 4 35.9 ±4.9 21.7
(18–24.9)
1.5 (3–46
cycles) 27.8 ±2.4 (∗)
n = 14 − 0.98◦
(∗)
n = 13 −0.94◦
Waller 1996 [52] 53 1.5 33.4 ±4.3N R  2.7 NR (+) −0.05 (+) +0.55
Waugh 2007 [53] 189 2 32.4 ±4.6
(21–40)
24.3 (range
not given) 5 28.9 ±3.9 (+)+ 1 . 6 ( +) −0.4
Bedford 2010 [48] 123 2 22.1 ±3.3
(19–35) 21.8 ± 2.5 6.8 ± 7.0 30.8 ± 4.1 (+)+ 1 .9( +)+ 0 . 7
Totals (Mean) 458 2.1 31.4 22.5 6.6 28.9 +0.53 −0.68
◦Based on a median split of % all cycles with ovulatory disturbances. “Normal” = 0%–33% of all cycles with ovulatory disturbances and “Ovulatory
Disturbances” = 34%–100% of cycles with ovulatory disturbances.
•“Normal” means normal menstrual cycle length with ovulation and a normal luteal phase length
# Numbers of cycles/year in which ovulation and ovulatory disturbances as well as cycle length were documented.
NR means not recorded.
Results of this cross-sectional study showed lower PdG
and E1C excretions across cycles in cases compared with
controls. All three summary measures of PdG were lower
in cases (peak, mean, and area under the curve with
P = .002–.006 ). E1C was also lower (with P = .01
to .008). Although not statistically signiﬁcant, anovulation
rates were higher in cases (14.8%) than in controls (8.8%).
The data suggest that lower BMD values are related to subtle
disturbances in ovulation and perhaps estradiol levels within
regular cycles.
The ﬁnal two cross-sectional studies failed to conﬁrm
a relationship between ovulatory disturbances and bone
change in premenopausal women [51, 53]. These studies
typically have measured ovulatory function in only one cycle
and/or did not document short luteal phase lengths that
are the most prevalent subclinical disturbances of ovulation
[51, 53]. It is likely that a cross-sectional study does not have
the power to show a bone-ovulation relationship because of
the great within-woman variability of subclinical ovulatory
disturbances.
3.2.5. Progesterone Therapy for Premenopausal Bone Loss
Prevention. If the above associations of ovulatory distur-
bances with less positive changes in bone hold true, women
with subclinical ovulatory disturbances who are currently
undiagnosed and overlooked as having bone risks might
be experiencing bone loss over many asymptomatic pre-
menopausal years.
Data on progesterone’s osteoblast-diﬀerentiation eﬀects
suggest that luteal phase “progesterone replacement” may
be an eﬀective treatment for SOD. So far, no progesterone
trial with bone endpoints has been undertaken, but there are
two published trials of physiologic dose (not depot) cyclic
medroxyprogesterone (MPA) of which we are aware, one
a randomized controlled trial in healthy, normal weight,
physically active women in their early 30s [15]a n do n e
an open although apparently randomized trial in under-
weight teenagers with amenorrhea or oligomenorrhea [52].
The prospective trial of cyclic medroxyprogesterone acetate
(MPA, 10mg/day for 12 days a month) for underweight
teenagers [52] is compared with the randomized, double-
blind placebo-controlled two by two factorial design trial of
cyclic MPA (10mg/day for 10 days a month) and/or calcium
supplementation (1000mg/d) [15]. Women participating in
this latter one-year trial diﬀered from those in the teen
study in being healthy, of normal weight, and physically
active. In addition, they had a range of menstrual cycle and
ovulatorydisturbancesincludinghypothalamicamenorrhea,
oligomenorrhea, or ovulatory disturbances within regular
cycles [15]. Bone change across one year was compared by
randomization to cyclic MPA or to placebo [15].
Women with regular cycles were required to have two
consecutive cycles with proof of ovulatory disturbances
by QBT before enrolment. Participants were stratiﬁed by
amenorrhea, oligomenorrhea, anovulation, and short luteal
phase cycles into one of four groups—(1) cyclic MPA (10mg
for 10 days a month or cycle days 16–25) with active calcium
(an additional 1000mg/d); (2) cyclic MPA with placebo
calcium; (3) placebo cyclic MPA with active calcium or (4)
both MPAandcalciumplacebos [15].Theprimary outcome,
BMD of L1-4 in the spine, was measured at the beginning
and the end of the year, as were body weight, height, and skin
folds. Women also recorded 3-day diet diaries every three
months and daily completed a Menstrual Cycle Diary [55]
recorddaily,aswellasrecordingtheirbasaltemperaturesand
exercise duration, type and mean exercise heart rates.
Results in the 61 women completing this cyclic MPA
trial showed that bone change over one year was positive
in those assigned to cyclic MPA with or without calcium
supplementation and averaged +1.7 ± 0.5( S E M )p e r c e n tJournal of Osteoporosis 7
(2 × 2A N O V AF = 19.43, P = .0001). The eﬀect of calcium
supplementation was not quite signiﬁcant (F = 3.34, P =
.073); however it prevented some bone loss (mean change
=− 0.7%, P = .28). Women assigned to both placebos lost
bone at a signiﬁcant rate (−2.0%, P = .005) despite being of
normal weight, having regular exercise and adequate calcium
intakes [15].
In a small open, apparently randomized (no clear RCT
methodology provided) trial of underweight or anorexic
teenagers with amenorrhea, who had inadequate calcium
intakes(lessthan1300mg/d),thegirlswereassignedtocyclic
MPA (10mg for 12 days/month, n = 5), oral contraceptives
(35μg ethinyl estradiol, n = 5), or placebo (n = 5) [52].
Young women in the same study who had oligomenorrhea
were assigned to cyclic MPA (n = 5) or placebo (n = 4).
Amenorrheic women on oral contraceptives appeared to
gain spine BMD while those on cyclic MPA and placebo
lost BMD [52]. However, these results are ﬂawed by the
diﬀerencesofendogenousestradiolbetweenoligomenorrhea
andamenorrhoeaaswellasbytheundernutritionofenrolled
young women, and the few participants.
3.3. Progesterone and Bone in Perimenopause
3.3.1. Bone Turnover Markers in Perimenopause. Although
perimenopause is understood to be a time of dropping estro-
gen levels, its hormonal changes are much more complex
than estrogen deﬁciency [10]. Hormonal perimenopausal
changes involve altered control of gonadotrophins [56], dis-
turbances of feedback of ovarian hormones at the pituitary
and hypothalamic levels, at least partly through the inhibins
[57], and erratic ovarian follicular growth despite decreasing
numbers of follicles [58]. Ovulation disturbance is one of the
consequences of these perimenopausal hormonal changes
[59], which, in turn, may accentuate the changes.
In the normal menstrual cycle, progesterone exerts
feedback on the hypothalamic GnRH pulse generator and
slows the frequency of GnRH pulses [60, 61]. However the
amplitude of the pulses is higher during the luteal phase
compared with the follicular phase. Towards the end of
the luteal phase, the decreasing progesterone concentrations
cause the GnRH-pulse generator to accelerate again. During
these few days of acceleration, GnRH-receptors in FSH-
producing cells are particularly sensitised, so that, for a few
days before, during and after ﬂow, FSH-levels rise [62]. This
mechanism is pronounced during perimenopause, when
increasing numbers of anovulatory cycles go hand in hand
with rising early follicular phase FSH levels.
This next section will ﬁrst review several studies of cross-
sectional BMD values and bone resorption markers related
to pre-, peri-, and postmenopausal status (Table 2). Results
of prospective changes in bone turnover markers in women
who diﬀered in reproductive status but were all over age 40
and changes in spinal BMD by QCT in untreated pre-, peri-,
and early postmenopausal women at baseline, two, and six
years [63] will be studied.
The majority of studies on perimenopausal bone change
have been conducted using dual (energy) X-ray absorp-
tiometry (DXA) of the hip and/or spine. DXA provides an
areal, rather than true volumetric summary measurement of
mineral content including both cortical and trabecular bone.
Cancellous or trabecular bone, which is more responsive to
hormonal changes, and measured volumetrically by QCT,
provides a more sensitive assessment of change in BMD
within the more metabolically active cancellous compart-
ment and may result in earlier detection of bone loss.
Since perimenopause is characterized by unpredictable
and unstable endocrinological changes, systematic com-
parison and classiﬁcation are diﬃcult. Eﬀorts to establish
standards for scientiﬁc comparisons and for clinical use
have led to ﬁve phases of reproductive transition, based
on endocrinological and clinical criteria deﬁned in interna-
tional boards such as the WHO Scientiﬁc Group [71]a n d
Workshops (e.g., Staging of Reproductive Aging Workshop
(STRAW) [72]), with the aim of achieving comparability of
scientiﬁc results on perimenopause. To date international
standardisationhasnotbeenachieved,andthenewlydeﬁned
criteria are still not used consistently. Therefore publications
reporting that they studied “perimenopausal women” may
include them either with premenopausal or postmenopausal
groups, as by Kushida et al. or Melton et al. in Table 2
[66, 68], or mix them with others to form a group of middle-
aged women such as ages 40–59 years [65] without applying
any distinct hormonal or menstrual cycle criteria. Another
wayofdealingwiththeproblemofdeﬁnitionhasbeentotake
change from premenopause to postmenopause over a time
courseofmanyyears,whichisonlypossibleinstudiessuchas
those published by L¨ o f m a no rR a v n[ 67, 69]( 5 - y e a rf o l l o w -
up, see Table 2). These studies, however, carry the risk of not
capturing perimenopause itself over such long intervals.
Amongstthepublishedcross-sectionaldata,onlyEbeling
etal.[64]andSowersetal.[70]studiedtrulyperimenopausal
groups of women. Ebeling found elevated bone resorption
rates and declining bone density in 118 perimenopausal
women. Sowers, in the baseline data of the multiethnic
participants (n = 2336 women aged 42–52) from SWAN,
the Study of Women Across the Nation, also showed that
increasedboneturnoverbeginsyearsbeforemenopause[70].
A meta-analysis of within-centre studies documenting
both perimenopausal and postmenopausal rates of spinal
bone loss earlier showed signiﬁcantly greater rates of loss in
perimenopause(−1.8v ersus−1.2%/year)[10].Thatanalysis
reported preliminary Melbourne Midlife Women’s Health
study results prior to their publication [73]. Using DXA,
this study showed that spine bone loss was increased during
perimenopause. However, in 224 untreated pre-, peri, and
postmenopausal participants (n = 78 early perimenopausal,
n = 12 late perimenopausal), the greatest amount of loss
occurred in the ﬁrst three years following the ﬁnal menstrual
ﬂow[73].Thismayhavebeenbecauseofinclusionoftheﬁrst
yearaftertheﬁnalmenstrualﬂowin“postmenopause”rather
than perimenopause [59], or because of the relative time lag
of DXA for bone changes aﬀecting mainly or exclusively the
trabecular compartment. Accordingly, early cycle elevated
FSH and low estradiol values, as are commonly found in
postmenopause, correlated with this increased loss [73].
Another study by Slemenda et al. showed increased
bone loss in 62 perimenopausal women from a total of 2318 Journal of Osteoporosis
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untreated women. Apart from low estrogen, bone loss in
this study was also associated with lowered serum androgen
levels [74]. The Michigan Bone Health Study cohort (513
women,aged25–45randomlysampledfromthepopulation)
documented that DXA of the spine was three percent
lower in perimenopausal than in premenopausal women
and that annual bone loss was signiﬁcantly elevated in per-
imenopausal women, when compared with premenopausal
participants [75]. These observations were conﬁrmed by the
even larger SWAN study (n = 2311) [76]. In the ﬁrst 4
years of this study with annual bone density measurements
and early follicular phase serum hormone values, this study
showed that in both baseline and follow-up, elevated FSH
levels were associated with decreased bone density, while
estradiol was not [76]. In both the Australian and USA large
studies, however, hormone values were only taken during
the early follicular phase, a time when FSH is often elevated
in perimenopausal women, estrogen is normally low, and
progesterone cannot be evaluated. So, despite the large size
and the power of these studies, they could only assess
hormonal eﬀects of the ﬁrst week of women’s menstrual
cycles, excluding the remaining 75% of potentially available
information [70].
Two prospective observational German studies
attempted to systematically characterize the changes in
bone metabolism associated with perimenopause. In the
ﬁrst study, serial bone turnover marker measurements
were made on 64 healthy women over age 40, who had
taken no exogenous hormones and were within three
reproductive life phases: premenopause (mean age 43.7
years, n = 20), perimenopause (mean age 50.3 years,
n = 24), and postmenopause (mean age 52.2 years, n = 20)
[78] .T h e s ep r o s p e c t i v e ,s e r i a lb o n em a r k e rm e a s u r e m e n t s
were ﬁrst made on four visits across one year (0, 3, 6, and
12 months). Parameters relating to bone resorption were the
urinary excretion of pyridinoline (PYD), deoxypyridinoline
(DPD), and N-terminal telopeptide (NTX), all corrected
for creatinine. As well, serum bone formation markers were
measured including osteocalcin (OC) and bone-speciﬁc
alkaline phosphatase (BAP) [78]. In these midlife women
with regular cycles, this study found a signiﬁcant decrease
over time for the bone formation marker BAP, leading to the
conclusion that the metabolic changes in bone remodeling
commonly associated with perimenopause (like the higher
estradiol levels and disturbed ovulation [10]) had already
begun in the late reproductive phase [30]. These participants
were followed for a second year [79], as well as eventually
over six [63] and nine years [80].
The six-year follow-up allowed for a longitudinal com-
parison of bone changes in pre- as opposed to peri-
menopausal and early postmenopausal women. Analysis of
QCT changes over time required classiﬁcation of women’s
reproductive status and its changes over time. Invariably
for all analyses, the perimenopausal period—during which
estrogen levels were still adequate—was associated with
the greatest reduction of QCT, with loss rates reaching
6.3%/year. Total bone loss diﬀered by pattern of individ-
ual women’s experiences of the transition from pre- to
postmenopause (one-way ANOVA P<. 05); the average
rate of loss was slower in the early postmenopausal years
[63].
The second prospective observational study was initiated
to further explore the drop in BAP observed in the ﬁrst
study and to systematically monitor bone turnover markers
in the follicular and luteal phases of serial cycles in 8 women
whose averaged age was 46 years. From a total of 170 cycles,
84 cycles with luteal phase serum sampling were analysed.
Categorical diﬀerences were calculated to detect individual
intracycle changes in bone metabolism. Figures 4(a) and
4(b) show the within-cycle change (luteal minus follicular
phase levels) of serum BAP (Figure 4(a))o rH P L C - e x t r a c t e d
urinary pyridinoline (PYD; Figure 4(b)) by the threshold
progesterone level used to document ovulation [81]. These
two ﬁgures show that both PYD and BAP patterns diﬀer in
ovulatoryandanovulatorycycles.Further,giventhatpositive
values mean increases in the luteal phase and negative values
mean luteal phase decreases, these data suggest that the
higher the progesterone level the more bone formation. As
mentioned earlier, decreased bone resorption markers in
the luteal phase occur because resorption continues to be
controlled by moderate luteal phase estradiol levels.
Seifert-Klauss and colleagues are currently conducting
the ongoing “PENO-Study” (Perimenopausale Knochen-
dichte [bone density] und Ovulation), which is a prospective
observational study over the course of two years. Its purpose
is to investigate menstrual cycles, hormonal values, bone
turnover markers, and changes in bone mineral density
(BMD) during the perimenopause to answer the following
question: do perimenopausal women with a higher rate of
anovulatory cycles have increased loss of bone density?
Inclusion criteria for this study are age >45 years, cycle
lengths no greater than 42 days, no use of exogenous
hormones during the 6 months prior to study onset, and no
medical reasons for low bone mass. Lumbar spine trabecular
BMD measurements are performed using QCT at baseline
and after two years. Participants note the beginning and end
of each cycle and used a cycle monitor to detect the day on
which there was a high probability of ovulation.
Results are available so far for 54 women (mean age
48.3 ± 2.3SD years) who have recorded 673 evaluable cycles
and had 132 luteal phase blood tests suitable for analysis.
QCT measurements at baseline show that 45 women had
normal bone density (mean 148.2 ± 19.3mg Calcium-
Hydroxyapatite (Ca-HA)/mL3), while nine had osteopenia
(mean 103.7 ± 7.3mg Ca-HA)/mL3.W o m e nw i t hn o r m a l
BMD at the beginning of the study, and those who main-
tained BMD levels within the normal range over two years,
were more likely to experience normal ovulatory cycles with
fewerovulatorydisturbancesthanthosewomenwhoseinitial
or two-year QCT values showed osteopenia. During the
course of this two-year study, the proportion of ovulatory
cycles related to QCT bone change (r =− 0.7, P<. 05)
(Figure 5). Also, as has previously been shown [59, 82],
progesteronelevelsdecreasedbeforecycleswithoutovulation
became common [77].
Although women are known to lose bone rapidly before
as well as after they become postmenopausal [10, 83], this
study adds to existing data by showing that this bone lossJournal of Osteoporosis 11
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Figure 4: Intra-cycle follicular-luteal phase change in two diﬀerent
bone turnover markers by the serum progesterone level used
as a threshold for ovulation. (a) shows the bone formation
marker bone-speciﬁc alkaline phosphatase (BAP) in serum, (b)
depicts changes in the bone resorption marker Pyridinoline (PYD)
extracted with HPLC from urine and normalized to creatinine
reprinted from [77]. Permissions provided.
is not simply due to the increased bone resorption caused
by the perimenopausal swings in estrogen levels but is also
related to progesterone levels and ovulatory characteristics.
3.4. Progesterone and Bone in Postmenopausal Women. Post-
menopausal women are more likely to experience fragility
fractures than are pre- or perimenopausal women. This
increased fracture risk is usually ascribed to estrogen
deﬁciency—but this state also includes progesterone “deﬁ-
ciency.” A number of published investigations have asked
two questions about the relationship of progesterone to
bone change in postmenopausal women. These research
questions are as follows. (1) Does progesterone therapy
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Figure 5: The 2-year-change of trabecular lumbar spine bone min-
eral density documented by Quantitative Computed Tomography
(QCT) is shown by rate of ovulatory cycles in 28 women with
complete ovulation data out of the 44 women studied prospectively
in the ongoing PEKNO-Trial. Assessed by a commercially available
ovulation monitor device, ovulation-likelihood was veriﬁed by
luteal phase serum sampling. The graph illustrates the signiﬁcant
linear relationship (r = 0.7; P<. 05) observed between the percent-
age of ovulatory cycles and BMD loss in pre- and perimenopausal
women. This ﬁgure is from a presentation on the interim analysis
by T. Wimmer and V. Seifert-Klauss to the Congress of the
German Menopause Society (Deutsche Menopausen Gesellschaft)
in Hamburg, November 6th 2009 (unpublished). The authors
provide permission.
prevent or treat osteoporosis in postmenopausal women? And,
(2) Does progesterone therapy add to the bone-positive eﬀects
of anti-resorptive therapies (such as estrogens, calcitonin, or
bisphosphonates)? This section and the next will review the
available human data to answer these two questions.
3.4.1. Progesterone Therapy for Postmenopausal Osteoporosis.
To determine whether progesterone is eﬀective treatment for
osteoporosis in postmenopausal women, changes in BMD by
DXA and/or QCT in four RCTs compared treatment with
progesterone or MPA with placebo. Gallagher, in the earliest
study, asked whether a high dose of the non-androgenic
progestin, medroxyprogesterone [MPA] eﬀectively treated
postmenopausal osteoporosis. The 20mg dose of MPA for
23 of 28 days did not prevent bone loss by spine dual photon
absorptiometry (DPA) [84]. Likewise, Table 3 shows bone
change in two further RCTs of more standard MPA doses of
10mg/d, 300mg/d of oral micronized progesterone (OMP),
or 20mg/d of progesterone cream. The net result of the
placebo-controlled trials with MPA was bone loss (−2.2%
per year) despite these MPA or progesterone therapies and
withnoapparentdiﬀerencefromthebonechangeonplacebo
(−2.4%/year).12 Journal of Osteoporosis
Table 3: Double-blind randomized controlled trials of percentage spine Bone Mineral Density (BMD) change per year in postmenopausal
women treated with Progesterone/Medroxyprogesterone (MPA) compared with placebo.
Author/year
and
reference
Total
number Age Bone site Years Drug and
dose Schedule Number
%B M D
Change
(Active)
Number
%B M D
Change
(Placebo)
Gallagher
1991 [84] 81 51.7 ±4.4 DPA∗
L2−4 2 MPA 20mg 23/28 days 20 Spine −2.5 20 Spine −3.8
Radius 20 Radius 0.0 18 Radius −2.4
Prior 1997
[85] 33 45 ±5
QCT
T12−L3
DXA
1M P A 1 0 m g D a i l y 1 8 Q C T −15 NA
• NA
WB+ WB −2.8 NA NA
FN++ FN −5.2 NA NA
Leonetti
1999 [86] 102 52.5 DXA
L2−4 1
∗P4 Cream
20mg Daily 43 Spine −1.4 47 Spine −1.0
T Hip 43 T Hip −2 . 54 7T H i p −1.0
Liu 2005
[87] 132 52.5 DXA
L2−4 2 +OMP 300 mg
Daily 15 Spine −1.0 23 Spine −1.0
FN 15 FN −0.52 3F N −0.0
MPA 10mg Daily 16 Spine −1.9 23 Spine −1.0
16 FN −1.1 23 FN −0.0
Mean %
Change
OMP & P4
Cream 58 Spine −1.2 70 Spine −1.0
MPA 36 Spine −2.2 43 Spine −2.4
∗P4:p r o g e s t e r o n e
+OMP: oral micronized progesterone
•NA: not available—this trial was controlled by conjugated equine estrogen and without a placebo.
One of the RCTs of MPA alone and bone change was a
unique one-year randomized blinded comparative study ver-
sus conjugated equine estrogen (CEE) in 41 premenopausal
women who had just undergone premenopausal abdo-
minal hysterectomy with bilateral ovariectomy for benign
problems [85]. CEE (0.6mg/day) was compared with MPA
(10mg/day) over one year [85]. All 41 women began study
participation after fasting blood and urine samples were
obtained on the morning they were discharged following
their surgery [85]. Results showed highly signiﬁcant rates of
spinalcancellousQCTbonelossinwomenonboththerapies
(−15% MPA, −8.3% CEE, P = .04). MPA also did not
prevent signiﬁcant bone loss in the whole body (−2.8%) and
femoral neck (−5.2%).
The results of this MPA versus CEE randomized com-
parative trial may provide clues to causes for major bone
loss despite progesterone/MPA therapy with their osteoblast
diﬀerentiating and bone formation eﬀects. On average at
seven days following surgery, bone resorption markers were
three to ﬁve standard deviations higher than premenopausal
levels.Theseboneresorptionmarkersdidnotdecreaseacross
a year of MPA therapy despite the fact that all women
were supplemented with 600mg of additional calcium/day
and gained approximately 2.5kg in weight [85]. These data
suggest that MPA does not decrease bone resorption. One
further randomized 2-year placebo-controlled trial of a
progestin and bone change is available. This study treated
early postmenopausal women with promegestone, a 19 nor-
progestin, or placebo and showed some prevention of bone
loss (−1.3% versus −4.5% on placebo, P = .05) [88].
Urinary calcium excretion was signiﬁcantly decreased in the
promegestone group, however, suggesting it may decrease
resorption rather than acting through the progesterone
receptor.
Taken together from this meta-analysis, the answer to
the ﬁrst question is as follows M P A / P r o g e s t e r o n ea l o n ei sn o t
eﬀectivetherapyforpostmenopausalosteoporosisbecauseithas
noorlittleeﬀecttocontrolboneresorption,thedrivingforce
in human bone loss and osteoporosis.
3.4.2. Progesterone as Co-Therapy with Antiresorptives for
Postmenopausal Osteoporosis. Yearly percent bone change
on co-therapy with an antiresorptive and progesterone or
MPA compared with the antiresorptive agent alone has
been studied in ﬁve randomized, double, blind controlled
trials to answer the second research question named above
(Table 4). Two of these were major studies in the bone ﬁeld
(Postmenopausal Estrogen Progestin Investigation [PEPI]
[89] and the Women’s HOPE trial) [90] .Am o r er e c e n ts t u d y
combined MPA 10mg/d with oral micronized estradiol inJournal of Osteoporosis 13
Table 4: Comparison of randomized double-blind controlled trials of bone change in postmenopausal women with osteoporosis comparing
combined estrogen [Conjugated Equine Estrogen (CEE) or Estradiol (E2)] plus progesterone or medroxyprogesterone (MPA) and
documenting percentage (%) change per year in Bone Mineral Density.
Author Type Number Age ±
SD Bone sites Years
Anti-
resorptive
mg/d
Progesterone/
MPA mg/d Number Combined %
bone change Number
Anti-R∗%
bone
change
Gallagher
1991 [84]
RCT not
blinded 81 52 ± 4
DPA
L2−4
SPA
2 0.3 CEE
23/28 days
MPA 10mg
23/28days 16 Spine +0.25 18 Spine +1.0
Radius Radius +0.0 Radius
−0.05
PEPI 1996
[89] DB-RCT 875 56 DXA
L2−4
3 CEE 0.625 MPA 2.5 mg/d 174 Spine +1.6 175 Spine +1.4
Total Hip
(TH) 174 TH +0.5 175 TH +0.5
Adachi 1997
[91] DB-RCT 98 54 DPA 1 CEE 0.625 MPA 10mg for
15d/mo. 33 Spine +2.7 34 Spine +1.9
Lindsay
2002 [90] DB-RCT 695 58 L2−4
DXA
2 CEE 0.625 MPA 2.5 mg/d 81 Spine +1.7 84 Spine +1.2
Total Hip
(TH) TH +1.3 TH +1.4
CEE 0.45 MPA 2.5 mg/d 87 Spine +1.5 91 Spine +1.1
TH +1.1 TH +1.0
Liu 2005
[87] DB-RCT 132 53 DXA
L2−4
2 E2 1mg/d MPA 10 mg/d 20 Spine +2.3 23 Spine +1.3
FN OME# FN +0.9 FN +1.0
Totals 330 Spine +1.7 425 Spine +1.3
•DPA: dual photon absorptiometry, SPA: single photon absorptiometry, DXA: dual energy X-ray absorptiometry.
∗Anti-R: antiresorptive therapy, #OME: oral micronized estradiol.
Note that the two estrogen-dose arms of the Lindsay study were considered as two diﬀerent studies in the mean spine bone change.
a dose of 1mg/d, versus the estradiol alone [87]. The results
of these RCTs show the mean change in spinal BMD on
co-therapy with daily low-dose MPA, and an antiresorptive
was slightly more positive (+1.7%/year) than with the
antiresorptivealone(+1.3%/year),adiﬀerenceofabout24%.
In both of the largest studies [89, 90], estrogen-progestin
spine results were noted to be signiﬁcantly more positive
than those related to the antiresorptive alone [89, 90]. This,
however, did not appear to occur when the progestin was
given cyclically [91], suggesting that daily progesterone is
needed to increase BMD in menopausal women. Therefore
the answer to the second question is as follows. Progesterone
daily co-therapy with estrogen is more eﬀective than estrogen
alone for postmenopausal osteoporosis.
The non-randomized clinical studies combining MPA
with an antiresorptive therapy show similar but even greater
increases in BMD on MPA and antiresorptive co-therapy
compared with the antiresorptive alone [92–94]. It is very
diﬃc u l tt oc o m p a r es t u d i e si nw o m e nw h oh a v eh a dh y s -
terectomy with/without ovariectomy because women with
hysterectomy, and certainly following ovariectomy, are much
more likely to be treated with estrogen than are women
with natural menopause; this represents confounding by
indication. The New Zealand studies examined older post-
menopausal women with high rates of bone loss who were
treated with CEE plus 5mg/d of MPA or with CEE alone—
thisone-yearstudysawa65%greaterspineBMDincreaseon
combined therapy (6.6%) compared with CEE alone (4.0%)
[93]. A prospective study also from New Zealand and in a
similar population looked at the rates of bone change in the
hip and spine when either CEE or transdermal estradiol was
paired with MPA [92] and compared with placebo. One-year
results were quite positive in the spine (+7.1%) and in the
femoral neck (2.9%) but there was no anti-resorptive alone
comparison in this descriptive study. Finally, a small pilot
study on a random sample of (n = 20) clinical patients
treated with MPA combined with an early bisphosphonate
(intermittent cyclic etidronate, Didrocal) compared their
bone change data with that from a meta-analysis of RCTs
of etidronate alone [95]. In this comparison, spine increases
were greater on MPA-antiresorptive co-therapy (+2.6%)
than on antiresorptive therapy alone (+1.8%); femoral neck
BMD increases on MPA co-therapy were also more positive
(+1.5% versus +0.5%) [94].14 Journal of Osteoporosis
So far in this paper, the fracture prevention shown in
the CEE-MPA and the CEE only arms of the Women’s
Health Initiative (WHI) trials has not been discussed [5, 96].
These are not only the largest studies of bone in women
randomizedtopostmenopausalhormonetherapyorplacebo
(n = 27,000 in both studies together), they are also the only
randomized, placebo-controlled studies to show fracture
prevention with ovarian hormone therapy. These data are
especially important since the study population was not
selected for low bone mass or osteoporosis risk factors.
Ideally we could compare the rates of fracture in the co-
therapy with the CEE-only arms but this is not possible
because each was in a diﬀerent randomization scheme and
had its own placebo group. We have requested collaboration
with WHI investigators in such an adjusted analysis.
3.4.3. Breast Cancer and Other Issues Relating to Proges-
terone/MPA Therapy in Postmenopausal Women. Data so far
suggest that progesterone or MPA co-therapy with estrogen
is more eﬀective for osteoporosis; however breast cancer
is an important clinical concern [96]. Combined hormone
therapy containing MPA has been repeatedly associated with
increased breast cancer risk [97–99]. The prospective E3N
observational study, following 80,000 French women over
eight years however, saw an increase in breast cancer risk
onlywithestrogenaloneorwithsyntheticprogestins,butnot
with oral micronized progesterone combined with estrogen
[99, 100]. Randomized controlled research on the breast
cancer risks with estradiol plus progesterone is needed.
Likewise, eﬀects of progesterone and various progestins
on intramammary estradiol metabolism are needed before
combined estradiol and progestin would be considered safe
or acceptable.
Other important non-bone issues in women with post-
menopausal osteoporosis are sleep disturbances and hot
ﬂushes and night sweats (vasomotor symptoms, VMS) that
have been linked to increased bone loss [101–103]. Oral
micronized progesterone is clinically useful for insomnia
and in a dose of 300mg at bedtime signiﬁcantly increased
total sleep time, decreased time required to fall asleep, and
increased early night REM sleep in a cross-over RCT [104].
That trial also showed that, after 21 days of treatment,
progesterone caused no lack of alertness or any cognitive
impairment in the morning [104]. Vasomotor symptoms,
that occur in about 70% of postmenopausal women and
a r es e v e r ei na l m o s t1 0p e r c e n t ,a r ee ﬀectively treated by
MPA [105, 106] and also by oral micronized progesterone
treatment [100].
3.5. Conclusions. Although the dominant osteoporosis
paradigm for women is, and should remain, centred on
estrogen, progesterone is emerging as an important partner
hormone that collaborates with estrogen. In vitro stud-
ies of human osteoblasts in culture, prospective studies
in adolescent, premenopausal, perimenopausal, and post-
menopausal women all indicate that progesterone—likely
working through bone formation pathways—plays an active
role in maintaining women’s bone and in osteoporosis
prevention.
Finally, although progesterone or MPA therapy does not
prevent bone loss when bone turnover is high, evidence
from a number of randomized controlled trials suggests
that progesterone as co-therapy with an antiresorptive agent
may have promise. Data on progesterone co-treatment and
fracture prevention are urgently needed, as is more informa-
tion about the microarchitectural and histomorphometric
changes during progesterone therapy.
Progesterone, a physiological ovarian steroid that is
normally secreted in high levels for two weeks per menstrual
cycle in ovulatory menstruating women, appears to have
complementary bone actions with estrogen and antiresorp-
tive therapies. Progesterone deserves to be studied more as a
new and emerging agent for achieving and preserving peak
bone mass, for prevention of pre- and perimenopausal bone
loss, and, with an antiresorptive therapy, in increasing BMD
and potentially decreasing fractures in postmenopausal
women.
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